ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ゾレドロン酸

Zoledronic Acid

HCID 68740
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
118072-93-8
標準SMILES
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O
InChIKey
XRASPMIURGNCCH-UHFFFAOYSA-N
分子式
C5H10N2O7P2
平均分子量
272.09 g/mol
単同位体質量
271.99632466

概要

Zoledronic acid is an imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position. It has a role as a bone density conservation agent. It is a member of imidazoles and a 1,1-bis(phosphonic acid).

名称と識別子

優先名称
Zoledronic Acid
IUPAC
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
現地名
ゾレドロン酸
英語名
Zoledronic acid
分子式
C5H10N2O7P2
分子量
272.09

名称と別名

Zoledronic acid118072-93-8ZoledronateZometaReclastAclasta(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acidZoledronic Acid AnhydrousAnhydrous Zoledronic AcidCGP 42446Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-DTXSID0042668
名称をさらに表示
ゾレドロン酸ゾレドロン酸ヘミペンタ水和物1-ヒドロキシ-2-(1H-イミダゾール-1-イル)エチリデンビスホスホン酸1-ヒドロキシ-2-(1H-イミダゾール-1-イル)エタン-1,1-ジイルビス(ホスホン酸)[1-ヒドロキシ-2-(1H-イミダゾール-1-イル)エチリデン]ビスホスホン酸1,1-ジホスホノ-2-(1H-イミダゾール-1-イル)エタノール[2-(1H-イミダゾール-1-イル)-1-ヒドロキシエチリデン]ビスホスホン酸2-(1H-イミダゾール-1-イル)-1-ヒドロキシエタン-1,1-ジイルビス(ホスホン酸)[1-ヒドロキシ-2-(1-イミダゾリル)エチリデン]ビスホスホン酸2-(1H-イミダゾール-1-イル)-1-ヒドロキシエチリデンビスホスホン酸[1-ヒドロキシ-2-(1H-イミダゾール-1-イル)エタン-1,1-ジイル]ビスホスホン酸1-ヒドロキシ-2-(1H-イミダゾール-1-イル)エチリデンジ-ホスホン酸[1-ヒドロキシ-2-(1H-イミダゾール-1-イル)-1-ホスホノエチル]ホスホン酸ゾレドロナートZoledronicZolidronic AcidZoledronic Acid APIOrazolBPH 91
ZOL 44670HZ18PH24(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acidNSC-721517[1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acidPhosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-Zoledronic Acid ActavisDTXCID8022668

物性

構造計算による物性

XLogP
-4.3
極性表面積
153 Ų
水素結合供与体数
5
水素結合受容体数
8
回転可能結合数
4
重原子数
16
形式電荷
0
複雑度
327

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP-4.2
Solubility · 2 件

Sparingly soluble

3.27e+00 g/L

Human Drugs · 6 件

Breast Feeding; Lactation; Bisphosphonates; Bone Density Conservation Agents; Diphosphonates;

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Physical DescriptionSolid

物理化学的性質

融点
193 · 193-2040C (dec)
沸点
764 · 764.0±70.0 °C(Predicted)
比重(密度)
2.13 · 2.13±0.1 g/cm3(Predicted)
貯蔵温度
Sealed in dry,Room Temperature
溶解性
水に可溶 (最大 2 mg/ml)。
外見
個体
酸解離定数(Pka)
1.41 · 1.41±0.10(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]

P261, P264+P265, P272, P280, P302+P352, P305+P351+P338, P321, P333+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesSkin Sens. 1 (100%)

毒性情報

Adverse Effects · 1 件

The commonly reported adverse reactions include pyrexia, headache, myalgia, pain in extremities, and arthralgia. Significant adverse effects associated with zoledronate include hypocalcemia, secondary hyperparathyroidism, acute phase response (APR), renal injury, atypical femur fractures, osteonecrosis of the jaw (ONJ), atrial fibrillation, and ocular inflammation.

Exposure RoutesIntravenous. Poorly absorbed (oral absorption is about 1% of what intravenous absorption is).
Toxicity Summary · 2 件

In the event of toxicity or overdose, no reversal agents are approved by the FDA for this drug. In a case report, a pediatric patient with osteogenesis imperfecta experienced a substantial 15-fold overdose of zoledronate. The patient received 4 mg (0.37 mg/kg) instead of the intended 0.27 mg (0.025 mg/kg) dosage, resulting in severe hypocalcemia and hypophosphatemia, necessitating calcium and phosphorus supplementation with ergocalciferol administration. Despite supportive care and hemodialysis initiation to address electrolyte imbalances and potentially eliminate excess zoledronate, the patient experienced multiple episodes of nonsustained ventricular tachycardia. This case underscores the need for prolonged monitoring and electrolyte supplementation in pediatric Zoledronate overdose cases to address potential complications, including severe hypocalcemia and hypophosphatemia.

化学と産業

薬理情報

ATC Code · 4 件

M05BA08

M - Musculo-skeletal system

QM - Musculo-skeletal system

M05BA08

Protein BindingZoledronic acid is 23-53% protein bound in plasma.
Pharmacodynamics · 1 件

Zoledronic acid is a third generation, nitrogen containing bisphosphonate that inhibits osteoclast function and prevents bone resorption. The therapeutic window is wide as patients are unlikely to suffer severe effects from overdoses and the duration of action is long. Patients should be counselled regarding the risk of electrolyte deficiencies, renal impairment, osteonecrosis of the jaw, atypical femoral fractures, bronchoconstriction, hepatic impairment, hypocalcemia, and embryo-fetal toxicity.

Mechanism of Action · 1 件

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Etidronic acid also inhibits V-ATPases in the osteoclast, though the exact subunits are unknown, preventing F-actin from forming podosomes. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. Nitrogen containing bisphosphonates such as zoledronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate. These components are essential for post-translational prenylation of GTP-binding proteins like Rap1. The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis. zoledronate also activated caspases which further contribute to apoptosis.

Biological Half-LifeZoledronic acid has a terminal elimination half life of 146 hours.
Metabolism/Metabolites

関連反応

115 件
反応記録を作成
HRID 730591 の反応式
HRID 730591反応物として
HRID 730592 の反応式
HRID 730592反応物として
HRID 730593 の反応式
HRID 730593反応物として
HRID 730594 の反応式
HRID 730594反応物として
HRID 730595 の反応式
HRID 730595反応物として
HRID 730596 の反応式
HRID 730596反応物として
HRID 730597 の反応式
HRID 730597反応物として
HRID 730598 の反応式
HRID 730598反応物として
前へ1 / 15 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
118072-93-8
PubChem CID
68740
DTXSID
DTXSID0042668
ChEMBL
CHEMBL4303669、CHEMBL924
ChEBI
CHEBI:46557
UNII
70HZ18PH24
EC Number
871-741-2
Nikkaji
J556.181G
色
白またはオフホワイト
安定性
2 · 購入日から2年間安定です。この蒸留水溶液は、-20°C で 2 か月間保存できます。
InChI
InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
InChIKey
XRASPMIURGNCCH-UHFFFAOYSA-N
SMILES
C(P(=O)(O)O)(P(=O)(O)O)(O)CN1C=NC=C1
CAS データベース
118072 · 118072-93-8(CAS DataBase Reference)

化学的性質

化学的特性White Solid

The action of zoledronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Zoledronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates such as zoledronate appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

Signs and Symptoms · 1 件

There is no experience of acute overdose. Two patients received zoledronate (32 mg) over 5 minutes in clinical trials. Neither patient experienced any clinical or laboratory toxicity. Overdosage may cause clinically significant hypocalcemia, hypophosphatemia, and hypomagnesemia.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Zoledronic acid

vLess-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

hs_code
2933399090
risk_code
21/22-36/37/38
hazard_code
Xi
safety_code
24/25-36/37/39
· 2 件

Zoledronic acid is not metabolized _in vivio_.

Zoledronate does not inhibit human P450 enzymes in vitro and does not undergo biotransformation in vivo. Route of Elimination: In 64 patients with cancer and bone metastases, on average (± s.d.) 39 ± 16% of the administered zoledronic acid dose was recovered in the urine within 24 hours, with only trace amounts of drug found in urine post-Day 2. Half Life: 146 hours

FDA Pharmacological Classification · 6 件

70HZ18PH24

ZOLEDRONIC ACID ANHYDROUS

Established Pharmacologic Class [EPC] - Bisphosphonate

Chemical Structure [CS] - Diphosphonates

Zoledronic acid anhydrous is a Bisphosphonate.

ZOLEDRONIC ACID

MeSH Pharmacological ClassificationAgents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
Absorption, Distribution and Excretion · 3 件

A 4mg intravenous dose reaches a Cmax of 370±78.5ng/mL, with a Tmax of 0.317±0.014h, and an AUC of 788±181ng\*h/mL. A 5mg intravenous dose reaches a Cmax of 471±76.1ng/mL, with a Tmax of 0.368±0.005h, and an AUC of 917±226ng\*h/mL.

Zoledronic acid is 39 ± 16% eliminated in the urine as the unmetabolized parent drug.

Zoledronic acid has a renal clearance of 3.7 ± 2.0 L/h.

Cellular LocationsCytoplasm
Metabolite PathwaysZoledronate Action Pathway

用途と製造

Uses · 2 件

Use (kg) in USA (2002): 1

For the treatment of hypercalcemia of malignancy. Also for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. In May of 2007, the drug was approved for treatment of Paget's Disease.

応用分野 · 2 件

説明Zoledronic acid is a white, crystalline powder that is available in vials for reconstitution for IV infusion over at least 15 minutes. It does not undergo metabolic transformation and does not inhibit CYP450 enzymes. Clearance of this agent is dependent on the patient's creatinine clearance, not on dose. Serum creatinine levels should be evaluated before every treatment. Zolendronic acid is contraindicated in patients with severe renal impairment.

使用Zoledronic acid induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho.

上流・下流製品情報

上流原料

三塩化りんりん酸2-(1H-Imidazol-1-yl)acetyl chloride1-イミダゾール酢酸1H-イミダゾール-1-イル酢酸エチル水和物

補足説明

定義ChEBI: An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.